SEARCH

SEARCH BY CITATION

Table S1. Dose schedule and patient characteristics of the recombinant mutated human tumor necrosis factor-α (rmhTNF-α) maximum tolerated dose (MTD) and safety study.

Table S2. Adverse events in cancer patients treated with recombinant mutated human tumor necrosis factor-α for seven consecutive days at different dose levels.

Table S3. Characteristics of the patient population in tumor response evaluation after treatment with recombinant mutated human tumor necrosis factor-α (rmhTNF-α).

Table S4. Tumor responses following treatment with recombinant mutated human tumor necrosis factor-α (4.0 × 106 units/m2/day) in different cancer patients.

Data S1. Phase I trial of a recombinant mutated human tumor necrosis factor-α (rmhTNF-α) in cancer patients.

FilenameFormatSizeDescription
CAS_2153_sm_dataS1andtableS1-4.doc112KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.